Results 201 to 210 of about 563,634 (267)

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket   +14 more
wiley   +1 more source

Reply to: Rethinking intra-arrest thrombolysis: the role of patient selection and timing. [PDF]

open access: yesResusc Plus
Ohshimo S   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy